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In the world of possible nonsurgical therapies for the re-duction of localized fat, intralipotherapy is now well estab-lished and in use for over 15 years: a widespread technique 
in the field of aesthetic medicine that involves the use of 
adipocytolytic substances (substances that lyse adipocytes) by 
direct injection into fatty tissue with a long needle. The avail-
ability of a broad range of preparations used to perform the 
technique, with nonstandardized dosages and nonstandard-
ized protocols, has created widespread confusion and a myri-
ad of results, which are often very different one from another.
The study aims to evaluate—based on the many years 
of multicenter experience of the authors—each aspect of 
the technique, namely, materials used, protocol, dosages, 
technique, postoperative management, and association 
with other methods.
MATERIALS	AND	METHODS
Population
From January 2010 to December 2015, the authors 
have conducted 187 intralipotherapy courses, qualifying 
3,590 doctors who were trained to use an CE-registered 
device,1 in the following countries: Italy, Spain, Portugal, 
England, Germany, Greece, Turkey, Poland, Slovenia, 
 Croatia, Norway, Czech Republic, Russia, Serbia, and Mid-
dle East (UAE, Saudi Arabia, Kuwait, and Qatar). In these 
6 years, the 3,590 physicians have used 808,000 vials to per-
form intralipotherapy treatments in different areas of the 
body in the way and according to the dosages described as 
follows in subjects suitable for the treatment aged between 
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Background: Reconstruction intralipotherapy is a term commonly used in the field of 
aesthetic medicine, above all in Europe, which defines a specific injection technique 
developed for the treatment of localized fat with substances that provoke the lysis of 
adipocytes by means of an injection directly into the adipose tissue with a long needle. 
The aim of this study is to define the technique in detail and everything that is associ-
ated with it, on the basis of years of multicenter experience by doctors who perform it.
Materials	and	Methods: From January 2010 to December 2014, 3,080 European 
physicians were trained in intralipotherapy technique, and approximately 152,500 
patients were treated. The adipocytolytic agent used is a Conformité Européene-
certified device. The technique, equipment, protocol, posology, postoperative 
management, and adverse events are described below.
Results: The intralipotherapy technique combined with the appropriate adipocytolytic 
agent has been shown to be effective in every zone on the average of 76.7% of the 
cases. The variability is due to the area treated and the patient. The standardization 
of the technique, homogeneity of the protocol, and the posttreatment management 
have been essential for standardizing the results and minimizing any adverse events. 
The latter occurred only in a small percentage of the cases, while those more serious 
have been extremely rare.
Conclusion: This study shows how the intralipotherapic technique, when performed 
properly with an appropriate adipocytolytic device and when proper precautions are 
taken, can be effective and safe for reducing undesirable subcutaneous fat deposits. 
(Plast Reconstr Surg Glob Open 2016;4:e1085; doi: 10.1097/GOX.0000000000001085; 
Published online 27 October 2016.)
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18 and 65 years old. The authors and their colleagues 
(total 37 doctors) treated 1,832 patients (Table 1).
Adipocytolytic	Agent
The adipocytolytic agent used was a Class III CE-marked 
medical device (approved in 2009) for the reduction of lo-
calized fat in combination with ultrasound therapy: Aqualyx 
(Marllor International, San Giovanni in Marignano, Italy) is 
a mix of biocompatible detergents with a short half-life and 
biodegradable materials (sodium salt of 3α,12α-dihydroxy-
5β-chol-6-en-24-oic acid 0.7%), slow release, immersed in 
a sugar matrix (polymer of 3: 6-anhydro-l-galactose and d-
galactose), and a buffer system.1,2
Patient	Selection
The patients presented with various forms and degrees 
of localized fat in the following areas: double chin, jowl, 
buffalo hump, pseudogynecomastia, back rolls, flanks, 
arm, abdomen, saddlebag thighs, inner thighs, and inner 
knee. They did not present with any exclusion criteria for 
the treatment: psychological (indecisive or immature per-
sonalities, anxiety, dismorphophobia, with fictitious disor-
ders, or family members disapproving the treatment),3,4 
minors, pregnancy, women who are lactating, obesity, se-
vere allergic reactions or known allergies to the device, 
severe autoimmune diseases, acute infections in progress, 
immunosuppressive diseases with weakened immune 
systems, organ diseases uncompensated, or functional 
deficits (diabetes, kidney failure, liver disease, severe dys-
lipidemia, dysthyroidism, etc.). Before the treatment was 
performed, the patient underwent an objective examina-
tion; informed consent and photographic documentation 
were made. Physical examination provided important in-
formation such as follows:
 Location, extent, and thickness of the localized adipos-
ity (essential parameters needed for calculating the 
quantity to be injected);
Local contraindications for the treatment are acute skin 
diseases (wounds, acute dermatological lesions);
Documenting the coexistence of additional blemishes 
such as irregularities, asymmetries, cellulite, vascular 
malformations, skin tightening, and stretch marks.
Intralipotherapy
The technique involves the following steps:
Marking the treatment area and access points (2–3 per 
area, opposing if possible) when the patient is in an 
orthostatic position (legs slightly apart, arms folded) 
and the calculation for the quantity of the device re-
quired (see dosage);
In each 8 mL vial, 0.2 mL of lidocaine 2% was added  before 
starting the injections, as suggested by the manufac-
turer. If the intralipotherapy needle is used (23 gauge 
× 10 cm), it is not necessary to perform additional 
anesthesia (topical or local) in the area to be treated 
because the treatment is minimally painful and well 
tolerated. In the case where a cannula is used instead 
of a needle, it will be necessary to perform a minimum 
infiltration of a local anesthetic (0.5 mL of a local an-
esthetic common to 2% infiltrate in the dermis with a 
30-gauge needle, creating a papule) at the site where 
the cannula will be introduced. This is due to the fact 
that to insert the cannula, you must first create an ac-
cess point with an 18-gauge needle and this can be par-
ticularly painful if performed without local anesthesia;
In a decubitus position, the best position according to the 
area to be treated, infiltration of the device is per-
formed after first disinfecting the area to be treated 
(Fig. 1);
From the access point that was marked, the needle is in-
serted into the subcutaneous fat parallel to the cutane-
ous surface, avoiding contact with the skin and muscle. 
The total amount of the device previously calculated to 
be used is distributed using a retrograde release with 
the intralipotherapy needle (a long, 23-gauge × 10 cm 
needle, very similar to the needles used for spinal an-
esthesia) and a fan technique, releasing 0.2–0.4 mL 
of product during each passage. The fan technique 
consists of an advancing and retracting movement of 
the needle, very similar to that used with liposuction 
(Fig. 2). It is a 3-step technique (Fig. 3):
Step 1: Introduction. The long needle is completely inserted 
into the subcutaneous fat. At this stage, the doctor must fo-
cus on where to direct the needle (direction and depth). 
Table 1. Data Related to the Treatment and Infusion-related Success Rates in Different Anatomical Areas
Treatment	per	Area
Area	Treated
Vials	Injected	per	
Session
Percentage	of	the	
Treatments
Range	of	the	
	Sessions	Performed
Interval	Between	
the	Sessions	(wk)
Medical	
	Evaluation	
(Percentage	
	Satisfied)	(%)
Patient		Evaluation	
(Score,	6–10,	
	Percentage	
	Satisfied)	(%)
Double chin/jowl 0.5–1.5 9.3 1–3 4–5 76.9 71.4
Buffalo hump 1–2 1.6 2–3 6 85.5 70.3
Pseudogynecomastia 2–4 2.2 2–4 4 74.3 62.9
Back rolls 2–4 6.5 2–4 6 77.3 68.6
Flanks 3–6 18.0 2–4 6 88.2* 72.4*
Arm 2–4 2.3 3–5 4 64.4 42.1
Abdomen 3–6 19.1 3–5 6 81.0 67.7
Saddlebag thighs 2–6 18.8 3–6 5–6 69.9 61.0
Inner thighs 2–4 12.1 3–5 4–5 63.1 51.3
Inner knee 1–2 10.1 2–4 7–8 68.7 63.3
*Higher value.
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Once he has decided where to place the needle, he pen-
etrates the skin with an inclination of 45° at the previously 
established point (usually at the margin of the treatment 
area which was previously outlined), passes the dermis, and 
advances the needle toward the set point. The needle is in-
serted with a constant uniform movement without varying 
the direction of the needle during this phase. In the event 
that the doctor realizes that the needle was not positioned 
correctly (ie, too deep or too shallow), the needle should 
be retracted without releasing the solution until it is reposi-
tioned to the initial starting position (needle slightly insert-
ed into the subcutaneous fat, without leaving the skin), and 
the first step is repeated. If the patient complains of sudden 
pain, it is a good indication that the needle is positioned 
incorrectly. The needle should not be palpable or visible 
and the skin should not be everted because it indicates the 
needle has engaged the dermis during the insertion.
 	Choose the direction and depth.
 	Advance the needle in a straightforward direction, 
without changing direction.
Step 2: Retraction. After the needle is properly positioned, it 
is retracted. When the needle is retracted, the dose of the 
therapeutic solution (0.2–0.4 mL) is released. At this stage, 
the doctor must focus only on the release of the solution, 
which must be uniform and in the correct amounts. The re-
traction is a passive movement, that is, the needle returns to 
its initial position and no special precautions must be taken.
 	Retract the needle without thinking to the direction.
 	It is preferable to release less solution than too much.
 	Press the plunger of the syringe using a gentle and 
constant pressure, interrupting the flow of the device 
before arriving at the initial starting position (approx-
imately 1 cm).
Step 3: Change of Direction. Changing the direction 
from the initial starting position. After the needle has been 
completely retracted, without removing it from the skin, 
change the direction by a few degrees and repeat step 1. 
At this stage, the doctor must focus only on the variation 
of the angle, taking into consideration the entire area to 
be covered with the fan technique (he must execute a suf-
ficient number of steps to homogeneously distribute the 
solution, considering the greater thickness of the central 
area and reduced thickness of the peripheral areas). The 
central zone must be infiltrated several times, varying the 
depth. In the peripheral areas, a single superficial treat-
ment is sufficient (respecting the basic rule: no palpable 
needle, the needle is not visible, the skin is not everted).
 	Do not make excessive changes to the angulation (a 
few degrees are sufficient).
 	It is important to assure that the needle changes di-
rection and does not return in the same direction.
Posology
Treatments were performed 4 to 7 weeks apart and un-
til the clinical result was obtained.
Dosage
It is necessary to distinguish the treatment of adiposity 
in the head and neck region from treatment in the rest of 
the body. In the first case, the calculation for the dosage 
must evaluate the extent of the subcutaneous fat, whereas 
in the second case, the extent and the thickness must be 
evaluated. The posological calculation that follows refers 
to the CE-registered device (1 vial contains 8 mL of the 
device).
In the head and neck region, a half vial is used for each 
25 cm2 (for example, a half vial for a double chin and a 
quarter vial per part in the mandibular border).
In the body, 1 vial for each 100 cm2 (10 × 10 cm) is used, 
on the average, for subcutaneous fat of a limited degree 
(pinch test <3 cm) and 1.5 vials for subcutaneous fat of a 
greater entity (pinch test >3 cm).
Clinical evidence has shown that larger dosages signifi-
cantly increase the risk of onset of adverse effects.5
Posttreatment	Management
After the treatment, the use of contenitive elastic sheaths 
or a pressure bandage is highly recommended during the 
Fig. 1. the image shows a patient placed in a lateral decubitus posi-
tion for the treatment of saddlebag thighs. the area to be treated and 
access points had previously been marked when the patient was in an 
orthostatic position. For didactic purposes, the two opposing fans were 
drawn. Centrally, the area with a greater thickness of fatty tissue has been 
marked. the adipocytolytic agent in the syringe is injected directly into 
the adipose tissue with the needle using a retrograde release. the intra-
lipotherapy technique with respect to mesotherapy allows a more even 
distribution of the adipocytolytic agent, a more accurate selection of the 
plane to be treated, the possibility to maneuver (either more superficially 
or deeper) reducing the risk of infiltrating the dermis and muscle.
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first 48 to 72 hours. These, in addition to  reducing the ini-
tial pain, which is typical during the first 12 to 24 hours, also 
reduce edema and in general, the posttreatment phase.
Lymphatic drainage or pressure therapies are also ad-
vised to reduce the postoperative phase and accelerate a 
full recovery (2 sessions per week for 2 to 3 weeks post-
treatment starting from the third day after the treatment).
Evaluation	of	the	Results
Aesthetic outcomes were evaluated by the authors and 
their colleagues (total 37 doctors) in 1,832 patients treated 
by them directly, using preoperative and postoperative pho-
tographic documentation. In patients who had been treat-
ed in several different areas simultaneously, each area was 
evaluated independently. Each case was assessed by two doc-
tors who did not perform the treatment; they did not know 
the characteristics of the treatment (number of sessions, 
the quantity infiltrated, and the doctor who performed the 
treatment). The question put to the two doctors was divid-
ed into two categories: liporeduction change---significant or 
nonsignificant. The outcome was considered positive only 
if observed by both doctors. The patients also evaluated the 
results: their level of satisfaction was rated and the occur-
rence of adverse events (especially minor ones that were 
very frequent) was evaluated by filling out an anonymous 
form in the waiting room and given to nonmedical person-
nel (the results were rated from 0 to 10, where 0 is “no re-
sult at all” and 10 is “the best result achievable”). In some 
cases, pre- and postultrasound and/or centimetric evalua-
tions were made. The postevaluations were not performed 
before 3 months after the last treatment (for the inner 
knee not earlier than 5 months). Follow-up ranged from 
a minimum of 3 months to a maximum of 24. Aesthetic 
outcome was evaluated only in patients who completed the 
right follow-up. Patients evaluated with variations of ±5% of 
initial body weight were not considered in this study. Minor 
adverse events were assessed by monitoring the activity of 
the 3,590 physicians' ability to use the device in the 6 years 
that were analyzed: requests for advice and communica-
tions with the reference trainers, reports from distributors 
in various countries, and the parent company.
RESULTS
Of the 1,832 patients treated, 77.95% (1,428) are fe-
male and 22.05% (404) are male. In total, 26.64% (488) 
patients were not taken into consideration in the study be-
cause they presented with a body weight variation greater 
than ±5%. The subjective evaluation of patients demon-
strated the success of the treatments (that is, a score ≥6) 
in 67.2% of cases. The medical evaluation performed by 
photographic comparisons (or with other methods, ie, 
ultrasound) showed therapeutic success in 76.7% of the 
cases (Figs. 4–7). The best results have been reported on 
hips, double chin, and buffalo humps. The worst results 
were obtained on the arms and inner thighs (Fig. 8). No 
significant difference was evaluated when comparing the 
results in males and females in the same area. However, 
irrespective of sex, localized android fat-type (abdomen 
and hips) showed increased responsiveness to treatment 
over the gynoid-type liporeductive adiposity (culot thighs, 
inner thighs, and inner knee).
As with other methodologies even with intralipother-
apy, there may be occasional adverse effects, which can 
be classified as major and minor. In both cases, they can 
be attributed to local phenomena. According to the litera-
ture5–7 and the experience of the authors, the only occur-
rences of systemic adverse events were allergic reactions 
(in our experience with Aqualyx <0.003%). Minor adverse 
Fig. 2. the sequence of images shows the correct execution of the intralipotherapy technique. the long 
needle is inserted and retracted several times to cover, with a fanning motion, the area to be treated.
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events are extremely common and can be considered as a 
normal consequence of the treatment.5,7,8 These include 
edema in the first 72 hours (88.76%), pain lasting more 
than 48 hours (48.54%), bruising (72.58%), and tran-
sient nodules (16.36%). Major adverse events are rare9: 
hyperpigmentation (<0.002%), permanent paresthesia/
dysesthesia (<0.01%), skin necrosis (<0.01%), permanent 
nodules (0.005%), and skin irregularities (<0.03%). Risk 
factors for occurrence of major adverse events are incor-
rect execution of the intralipotherapy technique (uneven 
release of the agent, bolus, and placement which is too 
superficial), patients over 60 years of age, overdosing, and 
a shortened interval between 2 treatments.
DISCUSSION
The use of prepared injectable materials for the reduc-
tion of subcutaneous adipose deposits dates back to the 
turn of the century. These preparations are all derived 
from the so-called Natterman formula (EPL Natterman—
Essentiale/Lipostabil, NATTERMANN & Cie GmbH—Co-
logne Germany)10 (Table 2) developed for the intravenous 
treatment of a number of diseases: hepatic steatosis from 
alcohol and conditions of dysmetabolism (diabetes, lipo-
protein over nutrition, obesity, and malnutrition), adju-
vant therapy for intoxication from toxic agents and by 
some groups of drugs (antituberculosis, antipsychotics, 
antiepileptics, and immunosuppressants), hypertriglyc-
eridemia and hypercholesterolemia type IV, IIb, IIa, and 
prevention of fat emboli.
The studies published at the beginning of the new mil-
lennium11–14 show the actual effectiveness for reducing 
unwanted fat, first in the lower eyelid, and then all other 
parts of the body.
In parallel, to affirm and spread preparations of this 
type for off-label use (or on the basis of scientific evidence 
used in a clinical situation not foreseen in the technical 
data sheet and/or the instructions for use), studies show 
that the actual agent capable of lysing the cell is sodium 
deoxycholate and not phosphatidylcholine.15–17 Today it is 
universally accepted that the adipocytolytic formulations 
based on phosphatidylcholine have a therapeutic effect 
(necrosis of the adipocytes) due to its solvent or sodium 
deoxycholate. The latter is a surfactant that emulsifies lip-
ids, a biliary acid produced in the liver and secreted into 
the intestine to digest dietary fats; when injected into the 
adipose tissue, it induces necrosis by means of emulsifica-
tion (micelles) of the adipocytes.18 Sodium deoxycholate 
and all the formulations containing it induce adipocy-
tolysis and not lipolysis.19 To date, despite the widespread 
use and almost worldwide diffusion, the preparations of 
phosphatidylcholine and sodium deoxycholate (FC/DC) 
still have not been endorsed by the competent authori-
ties for the treatment of localized fat; therefore, it con-
tinues to be used off-label. In Europe, only one Class III 
medical device has received CE certification (approved in 
2009) for the reduction of localized fat in combination 
with ultrasound therapy: Aqualyx (Marllor International, 
San Giovanni in Marignano, Italy) is a mix of biocompat-
ible detergents with a short half-life and biodegradable 
materials (sodium salt of 3α,12α-dihydroxy-5β-24-oic cho-
lanic acid 0.7%), slow release, immersed in a sugar matrix 
Fig. 3. intralipotherapy technique. a, the needle is inserted into the 
access point. B, the needle completely penetrates the adipose tissue 
parallel to the skin surface. C, the needle is retracted releasing 0.2 to 
0.4 ml of solution. D, Without removing the needle from the skin, 
its direction is changed. e, again the needle penetrates the adipose 
tissue repeating the same procedure as in point B. F, the solution is 
again released while retracting the needle as in (C). the procedure 
continues until the area of interest has been completely covered, 
forming a fan design into which small quantities of solution have 
been released.
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Fig. 4. Pretreatment and posttreatment photographs of the lumbar region of a 48-year-old female pa-
tient. two sessions with aqualyx (48 ml per session). the patient lost 3 kg during the period in which 
the intralipotherapy was performed.
Fig. 5. Pretreatment and posttreatment photographs of saddlebag thighs in a 34-year-old female pa-
tient. Five combine aqualyx-US sessions (40 ml per session). the patient did not undergo any weight 
changes during the period in which the intralipotherapy was performed.
Fig. 6. Pretreatment and posttreatment photographs of the abdomen of a 41-year-old female patient. 
Six sessions of FC-SD (50 ml per session). the patient did not undergo any weight changes during the 
period in which the intralipotherapy was performed.
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(polymer of 3: 6-anhydro-l-galactose and d-galactose), and 
a buffer system.1,2 In the United States, the Food and Drug 
Administration has recently approved Kybella (Kythera 
Biopharmaceuticals Inc., Westlake Village, California, 
approved on 04.29.2015), a sodium deoxycholate-based 
drug indicated for the treatment of double chin in adults 
(Table 3).20 Both Aqualyx and Kybella do not contain 
phosphatidylcholine in their composition, which makes 
them more effective in the treatment, but gives them less 
manoeuvrability.21,22
To the adipocytolytic substances based on DC formula-
tions, vitamin C has recently been added. Although they 
are still being studied and waiting for an initial assessment 
(for off-label use), they represent a real innovation in in-
tralipotherapy because—unlike the previously mentioned 
agents—they induce adipocyte apoptosis instead of necrosis. 
Fig. 7. Pretreatment and posttreatment photographs of flanks and back rolls of a 55-year-old female 
patient. Five sessions of aqualyx (48 ml per session). the patient did not undergo any weight changes 
during the period in which the intralipotherapy was performed.
Fig. 8. evaluation of results per area according to the medical assessment and the patient. Photographic 
comparisons, ultrasound evaluation, skinfold thickness test, and centimetric evaluation have not shown 
significant differences in evaluating results. Patient satisfaction has been considered with a score of 6 to 10.
Table 2. Composition of Essentiale 
Phospholipids–Lipostabil
Formula	of	Natterman
Phosphatidylcholine 5%
Sodium deoxycholate 2.5%
Benzyl alcohol 0.9%
Sodium hydroxide 0.26%
Vitamin E 0.1%
Sterile water quantum satis
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The vitamin C, in certain concentrations with ionic Iron add-
ed to it and diluted with double-distilled water, induces the 
Fenton reaction in the adipose cells with cell damage result-
ing from oxidation/free radicals and apoptosis.23–25
The intralipotherapy is the most suitable technique for 
administering adipocytolytic substances in subcutaneous fat. 
These substances are totally nonselective and induce cytoly-
sis directly in the area where the device was injected, unlike 
other substances used subcutaneously, leading to functional 
alterations.9 However, it is important to emphasize that it has 
been demonstrated in vitro and in vivo that DC decreases its 
ability to lyse cells in relation to the protein concentration of 
the tissue. This shows that the deterging effect of DC is prefer-
entially directed to adipocytes although other tissues with an 
elevated protein content are protected (muscle, etc.).26 The 
adipocytolytic substances need to be released directly into 
the fatty tissue as homogeneously as possible and at different 
levels. In the case of substances having a functional effect (ie, 
carnitine and theophylline), the recourse to the mesothera-
py method is justified because the release of boluses spaced 
apart at a predetermined depth ensures good homogene-
ity by diffusion through the concentration gradient on the 
same plane.27 Contrary to what is indicated in the Kybella20 
 explanatory leaflet, we strongly advise against using adipo-
cytolytic agents with the mesotherapy technique because of 
the high risk of irregularities of the skin (pseudocellulite ef-
fect) and nodules.28 The selectivity of nonsurgical liporeduc-
tion with the use of sodium deoxycholate is guaranteed by 
the injection technique. (i) The intralipotherapy allows tar-
geting only the subcutaneous adipose tissue without affect-
ing the dermis and deep structures (fascia, muscles, etc.). 
(ii) The intralipotherapy allows to distribute DC as evenly 
and smoothly as possible to ensure proper liporeduction, 
avoiding the formation of irregularities and treating local-
ized fat dimensionally, that is, considering an extension and 
a nonuniform thickness (thicker in the more central areas 
and thinner on the margins), similar to the surgical tech-
nique of liposculpture. (iii) The intralipotherapy reduces 
the number of cutaneous accesses drastically compared 
to traditional mesotherapy (1–3 to the area to be treated) 
reducing the risk of infections. (iv) The intralipotherapy 
reduces the risk of skin irregularities due to a distribution 
in boluses and an application that is too shallow as in me-
sotherapy. (v) The intralipotherapy reduces the risk of skin 
necrosis as the release is deeper and more homogenous.
Evaluations of histological biopsies taken 3 weeks post-
treatment show that even several days after the treatment, 
the cytolysis effect continues to act on the adipocytes. 
In the preparations, indicators of early and late damage 
Table 3. Composition of the Kybella (ATX-101) Drug
ATX-101
Sodium deoxycholate 1%
Benzyl alcohol 0.9%
Sodium phosphate dibasic 0.142%
Sodium chloride 0.438%
Sodium hydroxide 0.143%
Hydrochloric acid and sodium quantum satis
Hydroxide pH 8.3
Sterile water quantum satis
Fig. 9. Histological biopsy performed 3 weeks after treatment with a Ce-marked device. in the image 
are visible early signs of cell damage (cell swelling and cytoplasmic homogenization), late findings 
(duplication and division of the 2 phases of the cell membrane), and cell lysis (image of Professor 
Motolese).
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(Fig. 9) coexist. This is particularly evident with the CE-
approved device because the chemical formulation con-
trols a modulated aggressiveness combined with a slow 
release. The histological findings suggested that the inter-
val between sessions should be spaced further apart with 
respect to the past where the treatments were performed 
at 2-week intervals. Today we realize that it is essential to 
wait at least 4 to 7 weeks before the next session. This in-
terval is subject to change based on the area of the body 
treated (ie, the knee needs at least 8 weeks), the individual 
response, and the quantity used.
As in any technique, the intralipotherapy also has a 
technical failure rate and that deserves some consider-
ation. The difference in rates of success perceived by the 
patient (average 67.2%) and medical evaluation (76.7%) 
is mainly due to the fact that patients generally have a high 
expectation from the treatment. Furthermore, when pa-
tients rated, they did not have a means to compare the 
current status with the previous treatment that dates back 
many months before. Often patients do not remember the 
original situation and this leads to underestimate the re-
sult. Instead, physicians’ evaluators have at their disposal 
photographs, US, or centimetric evaluations of pretreat-
ment and posttreatment.
The variability of results on different anatomical ar-
eas treated is due to different intrinsic characteristics of 
the subcutaneous adipose tissue. Localized fat deposits 
that are prevalently hypertrophic have more therapeutic 
results unlike those prevalently hyperplastic and this is 
mainly due to two factors: (i) different tissue regenerat-
ing capacity (higher in hyperplastic forms) and (ii) the 
various vulnerabilities of sodium deoxycholate (higher in 
hypertrophic forms).
However, it must be stressed that to have a more cor-
rect and efficient evaluation of the results, the procedure 
needs deeper analysis and statistical tests.
Only recently have intralipotherapy cannulas (Fig. 10) 
been introduced. These, unlike the Klein cannulas and 
those used in liposuction, have unique characteristics and 
were specifically designed for this technique, allowing for 
an optimal flow and release of the adipocytolytic agent 
(minimum at each step, from 0.2 to 0.4 mL). The advan-
tages of the cannula consist in the fact that they reduce 
vascular damage and injury to other important structures 
(ie, nerves), reducing the risk of major adverse events 
(skin necrosis, permanent paresthesia/dysesthesia) and 
decreasing the number and extent of the bruising. The 
use of a cannula necessitates the application of a local an-
esthetic before creating the access site and subsequently 
to creating the access with an 18-gauge needle.
Unlike other authors, we strongly believe in the syn-
ergy between intralipotherapy and other techniques, in 
particular, the use of ultrasound and carboxytherapy. Ex-
ternal ultrasound has a damaging effect on adipose tissue 
through thermal agitation, which induces its interstitial 
fluids (most likely with a cavitation effect, proved theoreti-
cally but never demonstrated in vivo).29–32 The increase of 
fluids in the interstitial tissues induced by the adipocytolyt-
ic agent (inflammatory edema) provides a greater amount 
of substrate, which is exposed to the ultrasound for the 
reduction of the subcutaneous adipose tissue, which has 
already been damaged by the effect of injected surfactants 
from the intralipotherapy. Serial echography performed 
at time 0, 10 minutes, 1 hour, 6 hours, 24 hours, 48 hours, 
and 72 hours postintralipotherapy sessions have shown 
that the edema effect induced by the adipocytolytic agent 
reaches a maximum level between 6 and 24 hours (Fig. 
11). The ultrasound session should therefore be per-
formed 24 hours after the intralipotherapy session. In ad-
dition, weekly sessions are recommended. The difference 
between intralipotherapy alone and in combination with 
ultrasound is not success rate that has remained the same 
but consists essentially in the fact that ultrasound deter-
mines a more homogeneous and uniform result in subcu-
Fig. 10. intralipotherapy cannula can either be disposable or rester-
ilizable. the single hole has a diameter smaller than 1 mm and en-
sures an optimum flow (0.2–0.4 ml of product per passage).
Fig. 11. Serial images of the adipose tissue; it is evident that the edema induced by treatment with the 
adipocytolytic agent increases in the first 24 hours and then starts to reduce and disappear 72 hours 
posttreatment. the maximum level is reached between 6 and 24 hours.
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taneous fat reduced, without irregularity of surface, with 
no changes in tissue texture from that of the surround-
ing untreated, avoiding that anomalous effect that often 
shows after liposculpture treatments and intralipotherapy. 
The association with carboxytherapy33–37 showed a greater 
efficiency histologically when compared to intralipother-
apy alone. To the necrotic process induced by the intra-
lipotherapy detergents, clear signs of adipocyte apoptosis 
are seen (Fig. 12). The treatment with gas is performed 
immediately after the intralipotherapy treatment, with 
inoculations of 4 mL of medical carbon dioxide. The in-
oculation is made with a 30-gauge needle 13-mm-long 
placed perpendicular to the skin plane and submerged 
completely into the adipose tissue, which had previously 
been treated with intralipotherapy. The inoculations are 
made 3 cm apart from each other, the flow is 80 mL/min 
and the gas has a temperature of 42°C. Dr Amuso used 
intralipotherapy only in association with carboxytherapy, 
treating 47 patients: success rate has remained the same 
but he needed a lower number of sessions (1 session on av-
erage) and a shorter interval between sessions (1–2 weeks 
on average).
The importance of adequate training for the physician 
is essential and this has also been emphasized in the inter-
national field.1 The physician who wants to perform intra-
lipotherapy treatments must be able to deal competently 
with each anatomical district and to achieve maximum re-
sults with a minimum risk. For this reason, the company 
distributing Aqualyx has organized a course for certifying 
the use of the device.
CONCLUSIONS
Clinical evidence and scientific studies have proven 
the effectiveness of adipocytolytic substances for the non-
surgical reduction of antiaesthetic subcutaneous fat.1,5–
8,11–19,21,22,28 The products on the market that have obtained 
approval from competent bodies (CE and Food and Drug 
Administration) do not contain FC and have been proven 
to be more efficient with respect to first-generation prod-
ucts.1,2,20,38,39 However, all of them having a nonenzymatic 
mechanism of action, based only on a deterging effect, 
the selectivity is mainly determined by the position in 
which the substance is released. Nevertheless, among all 
the tissues, the adipose tissue is the most vulnerable be-
cause of poor protective factors (albumin and proteins in 
general).26
Intralipotherapy is the correct technique for adminis-
tering adipocytolytic agents because it allows them to be 
distributed evenly over the entire area and at all levels 
although avoiding the dermis and muscle. It is necessary 
that the practitioner must be adequately trained.1 The 
standardization of the technique (protocol, dosage, post-
operative management, etc.) must have basic references 
to obtain optimal results and minimize adverse events.
Roberto Amore, MD
University of Palermo
P.zza Alessandrini 2, Cecina
Livorno, Italy
E-mail: robertoamore@hotmail.com
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